STRATEGIC ADVISORY
Market Sizing & Growth Strategy
Where should you compete, invest or expand?
Whether you’re entering a new market, exploring an indication or evaluating portfolio growth, the challenge is knowing where the real opportunity lies.
FMR helps life sciences companies quantify market potential, identify growth opportunities and evaluate where to focus investment, combining market evidence, stakeholder insights and strategic analysis.
HOW BIG IS THE OPPORTUNITY?
Quantify addressable markets, eligible patient populations and potential demand to understand the scale of your opportunity.
WHERE IS THE GROWTH?
Identify unmet needs, underserved segments and emerging opportunities that could create new sources of growth.
WHERE SHOULD YOU COMPETE?
Compare markets, customer segments and competitive dynamics to identify where your business has the strongest potential.
WHAT GROWTH CAN YOU EXPECT?
Explore demand, adoption and market scenarios to evaluate potential outcomes and inform investment decisions.
Project Types
SIZE THE OPPORTUNITY
- Addressable market and patient-population sizing
- Patient flow and treatment pathway analysis
- Therapeutic area and indication opportunity assessment
PRIORITISE WHERE TO COMPETE
- Country and market attractiveness assessment
- Customer and stakeholder segmentation
- Competitive and unmet-need opportunity analysis
PLAN FOR GROWTH
- Market entry and expansion scenarios
- Demand, adoption and uptake forecasting
Relevant Case Studies
SELECT A CASE STUDY
Nine European countries | 295 oncologists | 1,060 patient records
The challenge: How can a company quantify patient populations and treatment opportunities across different breast cancer markets?
Our approach: FMR conducted two waves of quantitative oncologist research with patient record collection and desk research. The work examined HR+/HER2- and triple-negative breast cancer, disease stages, treatment lines, mutations and patient characteristics.
Business implications: Country-level patient and treatment evidence enabled comparison of market opportunities and informed geographic prioritisation and commercial planning.
Nine countries | 48 stakeholder interviews
The challenge: Where are patients diagnosed and treated, which centres influence care, and what growth opportunities exist in a rare disease market?
Our approach: FMR combined desk research and stakeholder interviews with KOLs, healthcare professionals and hospital stakeholders to investigate prevalence estimates, diagnosis and treatment, specialist centres and patient flows.
Business implications: Mapped treatment centres and patient pathways, clarified stakeholder influence and highlighted potential opportunities for future engagement and market growth.
France | 56 physicians | 333 patient cases
The challenge: Which patient profiles might be considered for a new antiretroviral treatment and what market potential could it have?
Our approach: FMR combined telephone and online physician research with case exercises involving 333 previously treated patients. The study examined treatment pathways, preferences, eligible patient profiles and potential switches from established therapies.
Business implications: Provided evidence for opportunity sizing, patient eligibility estimates, potential treatment gain and loss and positioning considerations.
Seven countries | Qualitative and quantitative phases
The challenge: Which countries, customer groups and purchasing channels offer the best opportunities for introducing a laboratory product?
Our approach: FMR interviewed and surveyed laboratory users and purchasing stakeholders in Singapore, Thailand, Malaysia, Saudi Arabia, South Africa, Turkey and Israel. The research assessed market size, brands, purchase criteria, competing products and buying channels.
Business implications: Provided market and competitive evidence to inform country prioritisation, product requirements, channel planning and launch pricing considerations.
France | 15 qualitative and 50 quantitative oncologist interviews
The challenge: What patient groups and treatment situations may offer the strongest opportunity for a proposed antiemetic treatment?
Our approach: FMR conducted 15 in-depth oncologist interviews and a quantitative survey with 50 oncologists to examine treatment algorithms, existing therapies, patient eligibility and potential switching.
Business implications: Provided evidence on eligible patient profiles, potential uptake and where the new offer might be positioned relative to current treatments.
EVIDENCE FOR GROWTH
We combine market intelligence, patient pathways and stakeholder insight to assess market potential and the assumptions shaping demand.
Forecasting and scenarios help your team compare opportunities and decide where to compete, invest or expand.
WHERE WILL YOU GROW NEXT?
Tell us the market, indication or portfolio decision you are considering.